Abstract: A canister is disposed in an underfloor regions ? which is surrounded by a muffler arranged under a floor panel at a rear end of a vehicle body, a rear differential gear unit arranged under the floor panel at a location adjacent to the muffler in a longitudinal direction of the vehicle body, and a rear suspension member arranged so as to cover the space between the muffler and the rear differential gear unit from the underside of the vehicle body.

Abstract: A canister is disposed in an underfloor regions ? which is surrounded by a muffler arranged under a floor panel at a rear end of a vehicle body, a rear differential gear unit arranged under the floor panel at a location adjacent to the muffler in a longitudinal direction of the vehicle body, and a rear suspension member arranged so as to cover the space between the muffler and the rear differential gear unit from the underside of the vehicle body.

Abstract: A promoter domain of 1816 bp or 441 bp in the upstream side of exon 1B of IAI.3B gene has a specifically high promoter activity in ovarian cancer cells. An adenovirus having this promoter domain inserted in the E1 domain thereof exhibits a specifically high cell proliferation inhibitory effect on ovarian cancer cells. Thus, it is efficacious in gene therapy for ovarian cancer.

Abstract: A cancer gene therapeutic drug of the present invention includes a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from A549 cell, 293 cell, SW626 cell and HT-3 cell, showing a potent antitumor effect. Because of use of such cell line having high antitumor effect both in vitro and in vivo as the carrier cell, the cancer gene therapeutic drug provides more potent antitumor effect in comparison to those of conventional carrier cells.

Abstract: A cancer gene therapeutic drug of the present invention comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration so as to make the oncolytic virus act on a tumor cell within the living body. For example, A549 cell can be used as the carrier cell. Non-proliferative adenovirus inactivated by UV irradiation can be used as the virus for immunological treatment, and a proliferative adenovirus having a tumor-specific promoter can be used as the oncolytic virus, for example.

Abstract: A promoter domain of 1816 bp or 441 bp in the upstream side of exon 1B of IAI.3B gene has a specifically high promoter activity in ovarian cancer cells. An adenovirus having this promoter domain inserted in the E1 domain thereof exhibits a specifically high cell proliferation inhibitory effect on ovarian cancer cells. Thus, it is efficacious in gene therapy for ovarian cancer.

Abstract: The base sequence for the expression of a therapeutic gene and the medicament for gene therapy are disclosed. There is also disclosed the base sequence for the expression of a therapeutic gene, said sequence being shown in any one of from (a) to (d) and capable of directing the expression of the therapeutic gene specifically to squamous epithelium: (a) the base sequence set forth in SEQ ID NO:1 in the Sequence Listing; (b) the base sequence set forth in SEQ ID NO:18 in the Sequence Listing; (c) the base sequence set forth in SEQ ID NO:17 in the Sequence Listing; and (d) the base sequence set forth in SEQ ID NO:16 in the Sequence Listing. Moreover, there is disclosed the medicament for gene therapy containing a therapeutic gene downstream any of the above-mentioned base sequences, capable of directing the expression of the therapeutic gene specifically to squamous epithelium.

Abstract: An electronic device which includes at least one semiconductor chip with at least one circuit element thereon and connection patterns thereon being connected to the circuit element or elements. The connection patterns comprise a lower connection pattern, which is standardized and widely applicable to many kinds of circuits, and an upper connection pattern, which is positioned on the upper side of said lower connection pattern. The upper connection pattern and the lower connection pattern are connected in conformity with the desired circuit to be obtained.

Abstract: A plurality of logic circuits having log in-out functions are connected in sequence. A clock distribution circuit is connected to each sequential logic circuit via a corresponding one of a plurality of bidirectional lines. A mode designation signal is supplied in common to each sequential logic circuit and the clock distribution circuit. A sequential logic circuit selection signal, which selects one of the sequential logic circuits, is supplied to the clock distribution circuit. A clock signal is supplied from the clock distribution circuit to each sequential logic circuit via the bidirectional lines in the clock mode. Log in data is supplied from the clock distribution circuit to the sequential logic circuit via a specific bidirectional line in accordance with the sequential logic circuit selection signal in the log in mode.